McFarland L V
Department of Medicinal Chemistry, University of Washington. Correspondence to author at Biocodex, Inc., 1910 Fairview Avenue East, #208, Seattle, WA 98102, USA.
Curr Gastroenterol Rep. 1999 Aug;1(4):301-7. doi: 10.1007/s11894-999-0113-4.
Bacterial and viral diarrhea remain important causes of morbidity and mortality throughout the world. Current concerns with medical costs, increasing frequency of antibiotic resistance, and overuse of antibiotics in general have redirected therapeutic approaches for diarrhea from traditional drugs to the use of living therapeutic organisms. Awareness of the important role of normal flora in the microecology of the intestines in fighting infection, along with the recent availability of well-controlled clinical trials for these agents, has brought microecologic therapies to the forefront of clinical practice.
细菌性和病毒性腹泻仍是全球发病和死亡的重要原因。当前对医疗成本的担忧、抗生素耐药性频率的增加以及抗生素的普遍过度使用，已将腹泻的治疗方法从传统药物转向使用活性治疗生物。认识到正常菌群在肠道微生态中对抗感染的重要作用，以及近期这些制剂有了严格对照的临床试验，使得微生态疗法成为临床实践的前沿。
